Spots Global Cancer Trial Database for Abemaciclib in Patients With Oligodendroglioma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Abemaciclib in Patients With Oligodendroglioma

Official Title: A Single-Arm, Open-label, Phase II Study Evaluating the Efficacy and Safety of Abemaciclib in Patients With Recurrent Oligodendroglioma

Study ID: NCT03969706

Conditions

Oligodendroglioma, Adult

Interventions

Abemaciclib 200 MG

Study Description

Brief Summary: This is a phase II, single arm, open label study looking how well a drug called abemaciclib works in patients with recurrent oligodendroglioma

Detailed Description: Primary Objective: • To determine the efficacy of abemaciclib for recurrent oligodendroglioma, as measured by the estimated proportion of patients alive without disease progression at 6 months from study enrollment (PFS-6) Secondary Objectives: * To evaluate the safety and tolerability of abemaciclib in recurrent oligodendroglioma * To estimate the objective radiographic response rate (ORR) associated with abemaciclib in recurrent oligodendroglioma * To determine the median progression-free survival (PFS) and overall survival (OS) of patients with recurrent oligodendroglioma treated with abemaciclib * To determine ORR, PFS, and OS in the subgroup of recurrent oligodendroglioma patients with tumor CIC gene mutations Exploratory Objectives: * To measure pharmacodynamic markers of abemaciclib activity on oligodendroglial tumor cells * To identify pre-treatment tumor characteristics that are associated with response to abemaciclib recurrent oligodendroglioma